Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer : An Austrian Multicentre Study

Enfortumab vedotin (EV) offers a new treatment option for people with advanced or metastatic bladder cancer for whom other therapies such as chemotherapy or immunotherapy are no longer effective. An analysis from Austria, which included 128 patients, shows that EV is effective and tolerable in practice. In 31% of patients, the tumour was significantly reduced in size, and in 9% of cases it disappeared completely. On average, patients lived almost 11 months longer, with the health status and absence of liver metastases improving the chances of success. Despite side effects, which occurred in around a quarter of those treated, the therapy was easy to carry out.

Niedersuess-Beke, D., Mayrhofer, K., Krauter, J., Schnabel, S., Gampenrieder, S. P., Miechowiecki, J., Kiesl, D., Luger, F., Pfuner, J., Wiesinger, C., Vallet, S., Andalibi, H., Vais, D., Banner, A., Stoiber, F., Spielgelberg, J., Barth, D., Bauernhofer, T., Aufderklamm, S., ... Pichler, R. (2024). Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study. Clinical Genitourinary Cancer, 102278. Artikel 102278. Vorzeitige Online-Publikation. https://doi.org/10.1016/j.clgc.2024.102278